Prediabetes is an intermediate stage between clinical diabetes and normal glycaemia. Patient with prediabetes condition are more susceptible to diabetes and its associated cardiovascular disorder and diseases. Early known of prediabetes subjects reduces the development of diabetes and cardiovascular diseases. Pioglitazone, a thiazolidinedione (TZD) that is peroxisome proliferator-activated receptor (PPAR-γ) agonist’s insulin sensitizer, is known to reduce risk of atherosclerosis in prediabetic and diabetic subjects. Various preclinical and clinical studies have been shown the protective effect of pioglitazone on atherosclerosis in prediabetic and type-2 diabetic patients. Neutralization of cardiovascular risk factor associated with insulin resistance was turn out to be more important than its effect on blood glucose in spite of its controversy of bladder cancer.
Loading....